ALTTO test of dual HER2 blockade finds single agent remains the gold standard

June 1, 2014, Mayo Clinic

In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).

Results of the phase III clinical trial, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study), demonstrated that adding lapatinib to trastuzumab and chemotherapy did not improve patient outcome (defined as disease-free survival or overall survival), and that use of lapatinib significantly increased toxicity.

"These findings suggest that standard adjuvant (post-surgery) treatment for early stage HER2-positive breast cancer should remain trastuzumab in combination with chemotherapy," says Edith A. Perez, M.D., deputy director at large of the Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida.

"The ALTTO trial did not confirm the working hypothesis that adding lapatinib to trastuzumab, either concurrently or sequentially, would improve patient outcome (which was the primary endpoint)," she says. "These results were surprising and very important, as we had hypothesized and hoped that dual blockade of HER2 using two anti-HER2 agents would provide more benefit compared to single anti-HER2 therapy."

Dr. Perez added that the findings were additionally disappointing in that they did not confirm the benefit of using both anti-HER2 therapies predicted from the NeoALTTO clinical trial, which tested the therapies before cancer surgery (called neoadjuvant therapy). Some important positive results were seen in ALTTO, such as better outcome than expected for the overall group of patients, and a low risk of cardiac toxicity.

The 8,381-participant, 44-country phase III clinical trial was supported by The North American Breast Cancer Group (NABCG), based in the United States, and the Breast International Group (BIG) in Brussels, Belgium, the National Cancer Institute and Glaxo SmithKline. NABCG consists of six National Cancer Institute (NCI)-funded clinical trials cooperative groups. NCI is part of the National Institutes of Health.

Dr. Perez and Martine Piccart, M.D., Ph.D., professor of oncology at the Université Libre de Bruxelles, Belgium, are co-chairs of ALTTO. Dr. Piccart is lead investigator for BIG, which she founded in 1996. She presented results of NeoALTTO at the 2013 San Antonio Breast Cancer Symposium.

Dr. Perez predicts that the ALTTO results will be far-reaching in that they suggest that improved pathological complete response (pCR) in neoadjuvant clinical trials of patients with HER2-positive breast cancer may "not be predictive of improved long-term outcome of specific treatment in the adjuvant setting."

When therapy is given before surgery (called neoadjuvant therapy), pathologists can examine excised breast tissue for evidence of pCR—complete absence of cancer. Researchers and physicians have wondered, however, if pCR after neoadjuvant treatment is indeed linked to better outcomes for early stage HER2-positive breast cancer.

"The pCR measure from neoadjuvant is increasingly being used as a surrogate marker of outcome in adjuvant studies. The results of ALTTO suggest that pCR is not a factor that reliably predicts the long-term benefit when comparing two treatments," Dr. Perez says.

"The fact is that these ALTTO adjuvant results call into question the entire way care and research have been leaning in the last few years—which is to rely on pCR from neoadjuvant studies as surrogates of long-term outcome," she says. "We believe these results will be difficult for the field to absorb, but will ultimately guide our clinical research."

Specific findings from ALTTO will be presented at ASCO.

Explore further: Researchers to present event-free and overall survival results from NeoALTTO trial

Related Stories

Researchers to present event-free and overall survival results from NeoALTTO trial

December 11, 2013
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented ...

PIK3CA gene mutations make HER2- and hormone receptor-positive breast cancers treatment-resistant

December 12, 2013
Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more ...

Experts issue treatment guidelines for aggressive form of breast cancer

May 5, 2014
(HealthDay)—Two sets of guidelines for treating patients with an aggressive form of breast cancer have been released by the American Society of Clinical Oncology (ASCO).

Researches discovered genes that predict whether trastuzumab will work for breast cancer patients

December 8, 2012
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a large number of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in ...

High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab

December 11, 2013
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at ...

Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer

January 16, 2012
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.